A third case of formiminotransferase deficiency syndrome was described, which was associated with megaloblastic-pyridoxine-folic acid-responsive anemia of probably congenital origin.
The occurrence of megaloblastic pyridoxine-folic acid-responsive anemia was not observed in two cases of formiminotransferase deficiency syndrome previously reported by us.
Formiminotransferase deficiency syndrome1,2 was firstly discovered by us as a new inborn error of folate metabolism which was characterized by 1) mental retardation, 2) hyperfolic acidemia, and 3) an excessive urinary excretion of formiminoglutamic acid (FIGLU) following an oral dose of L-histidine. A definite diagnosis of this syndrome was established by demonstrating a defective activity of formiminotransferase in the liver specimens obtained from patients in question. Physical examination revealed a pale boy with a slightly distended abdomen. Auscultation on the lungs and heart gave no abnormality. The liver was palpable two finger breadths under the costal margin and soft in consistence. The spleen was not palpable. There was no lymphadenopathy. Deep tendon reflexes were normal and no pathologic reflexes were elicited. X-ray films of the chest, extremities and skull revealed no abnormality. The circumference of the head measured 39 cm, that of the chest 40 cm, body length 56 cm (normal 60.9 cm) and bodyweight 5.34 kg (normal 6.3 kg). Serum phospholipids and total lipids were normal, but serum cholesterol was ranging from 64 mg/100 ml to 80 mg/100 ml before pyridoxine therapy and slightly increased to the levels of 80 mg/100 ml (Jan . 6, 1967 ) and of 102 mg/100 ml (May 4, 1967) after the pyridoxine therapy. AICA loading test:6 Urinary excretion of AICA was found to be 0.13 mg/kg/ day and 2.14 mg/kg/day before and after an oral dose of AICA, 20 mg/kg (June 1967), respectively. Urinary AICA after the oral dose was considered to be increased above the normal limit of 1.5 mg/kg/day. Histologic findings of the liver specimens obtained by surgical biopsy on Dec. 15, 1966 revealed hemosiderin deposits in hepatic cells and Kupffer's cells and round cell infiltration of slight degree in the portal tracts (cf. Fig. 1 ). Pneumoencephalography carried out at the age of 1 year 5 months revealed that Evans' ratios were 0.34 on the right and 0.30 on the left side and the third ventricle was 8 mm in diameter, and that there was air accumulation suggestive of diffuse cortical atrophy of frontal areas (cf. Fig. 2 ).
Laboratory findings
At the age of 1 year 8 months the patient could walk with support but speak only a few words. Fig. 2 . Pneumoencephalogram of our own patient showed that Evans' ratio was 0.34 on the right, 0.30 on the left side, the third ventricle being 8 mm in diameter.
There was air accumulation suggestive of cortical atrophy. Hematologic findings (cf. Table 7 and Fig. 3 ): After admission his anemia persisted and repeated blood transfusions were required to maintain his red cell counts appropriately, until pyridoxal phosphate was administered. The intra muscular injections of pyridoxal phosphate consisting of 100 mg daily for 8 days and 50 mg daily for next 7 days resulted in a remarkable increase in reticulocyte count and a gradual increase in erythrocyte count.
In bone marrow smears megaloblastoid cells and ringed sideroblasts were found on February 1, 1966, when the patient was 3 months old. After pyridoxine therapy, both megaloblastoid cells and ringed sideroblasts still persisted in the bone marrow smears examined on June 10, 1967 (cf. Table 7 and Fig. 3 ). Folic acid was administered by intramuscular injections in a daily dose of 10 mg for consecutive 9 days, with a marked reticulocyte response (cf. Table 7 and Fig.  3 ). After the folic acid therapy, ringed sideroblasts decreased markedly in number (July 27, 1967), but megaloblastoid cells showed a slight decrease in number (cf. Table 7 ). 1) An anemia was found soon after birth and both ringed-sideroblasts and megaloblastoid cells were found in bone marrow smears examined at the age of 3 months, 2) after pyridoxine administration, a remarkable rise in reticulocyte count followed by an increase in erythrocyte count ensued, but megaloblastoid cells and ringed-sideroblasts still persisted in bone marrow smears repeatedly examined thereafter, and 3) there was no increase in urinary excretion of xanthurenic acid following an oral loading of tryptophane which was carried out before pyridoxine administration was instituted. a) The first is that formiminotransferase deficiency is a primary congenital lesion of our own patient and that it leads to subsequent development of sidero blastic-megaloblastic pyridoxine-responsive anemia. This assumption is derived from the reason that a defective activity of formiminotransferase gives rise to an impaired utilization of folic acid, that is, 'functional deficiency'18 of folates available for hematopoiesis, thus leading to development of megaloblastic changes in the bone marrow, and the resulting impaired hematopoiesis induces an elevation in serum iron levels,19"20 the latter leading to an increase in incidence of sideroblasts in the bone marrow. 21 As an evidence supporting this conception, it may be worthy to note that ringed-sideroblasts observed in the bone marrow smears were markedly reduced in number after the folic acid therapy was instituted in our own patient (cf. b) The second is such a possibility that formation and/or function of formi minotransferase system may be dependent on pyridoxine in a similar way, as the anemia of our own patient is pyridoxine responsive. This speculation may arise from the results reported by Vitale et al. 22 on one hand and those reported by Harris 21 on the other ; in 1966, Vitale et al. found that formiminotransferase of the liver was markedly decreased in rats with iron deficiency and suggested a possibility of requirement of iron for function and/or formation of formiminotransferase system; in 1964, Harris investigated the role of pyridoxine in heme biosynthesis of two adult cases of megaloblastic-pyridoxine-responsive anemia and concluded that pyridoxine was necessary for release of heme from mitochondria of reticulocytes taken from these patients before pyridoxine therapy was instituted. 
